Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 17, 2017L’acquisizione espande il portafoglio di prodotti dell’azienda nel settore della cardiologia strutturale ed incrementa le opzioni di trattamento per i pazienti con patologie valvolari cardiache
Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi di aver concluso l’acquisizione di Symetis SA, una società privata svizzera operante nel settore della cardiologia strutturale...
-
May 17, 2017
Boston Scientific ha annunciato oggi i risultati positivi dallo studio clinico REPRISE III presentati nell’ambito del programma scientifico del congresso EuroPCR di Parigi. I dati dallo studio...
-
May 16, 2017Acquisition Expands Company’s Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...
-
May 16, 2017
Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated...
-
May 16, 2017Die Übernahme erweitert das Portfolio des Unternehmens im Bereich Structural Heart und vergrößert das Angebot zur Behandlung von Patienten mit Herzklappenerkrankungen.
Die Boston Scientific Corporation hat heute den Abschluss der Aquisition der Symetis SA, eines privaten, im Bereich struktureller Herzerkrankungen tätigen Schweizer Unternehmens, das sich auf die...
-
May 16, 2017
Boston Scientific hat heute in Paris im Rahmen des jährlichen EuroPCR-Programms die positiven Daten der klinischen Studie REPRISE III präsentiert. Die Daten zum LOTUS™-Klappensystem, einem...
-
Apr 25, 2017Boston Scientific today announced results from the RANGER SFA trial for the Ranger™ Paclitaxel-Coated PTA Balloon Catheter at the Charing Cross Symposium, in London. Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.
The prospective, randomized, controlled trial, comparing the Ranger DCB to uncoated PTA balloons, included 105 patients with femoropopliteal lesions, at ten centers in Europe. Results demonstrate...
Mar 16, 2017Extended battery life of Boston Scientific devices attributed to reduction in replacement procedures and complications; has potential for significant cost savingsToday, the National Institute for Health and Care Excellence (NICE) issued medical technology guidance recommending the use of Boston Scientific Corporation (NYSE: BSX) cardiac resynchronization...
- Mar 16, 2017Si ritiene che la durata prolungata della batteria dei dispositivi di Boston Scientific contribuisca alla riduzione degli interventi di sostituzione e delle complicanze e che possa potenzialmente determinare risparmi economici significativi
Oggi, il National Institute for Health and Care Excellence (NICE) ha emanato delle indicazioni mediche e tecnologiche nelle quali si consiglia l’uso dei defibrillatori per la terapia di...
- Mar 16, 2017Die verlängerte Funktionsdauer der Geräte trägt zu einer Reduktion von Wechseleingriffen und damit verbundenen Komplikationen bei und kann so zu signifikanten Kosteneinsparungen führen
MARLBOROUGH, Mass., USA (16. März 2017) Das britische National Institute for Health and Care Excellence (NICE) hat heute Leitlinien zur Anwendung medizinischer Technologie herausgegeben, die für...